Catherine Thieblemont

Title: The Innovative Contributions of Catherine Thieblemont

Introduction

Catherine Thieblemont is a prominent inventor based in Paris, France. She has made significant contributions to the field of medical research, particularly in the area of lymphoma treatment. With a total of 2 patents, her work focuses on methods that enhance the understanding and treatment of lymphomas.

Latest Patents

Catherine Thieblemont's latest patents include innovative methods for determining the metabolic status of lymphomas. One of her patents provides an in vitro method for assessing the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells. A low level of GAPDH expression is indicative of oxidative phosphorylation (OXPHOS) status. Additionally, she has developed a method for predicting the responsiveness of patients afflicted with lymphoma to treatments involving metabolic inhibitors. This method also relies on measuring GAPDH expression levels in lymphoma cells. Another significant patent relates to predicting patient responsiveness to anti-CD20 antibody treatments, which involves measuring GAPDH expression in B cells obtained from patients.

Career Highlights

Catherine has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Assistance Publique-Hôpitaux de Paris. Her work in these institutions has allowed her to contribute to groundbreaking research in the medical field.

Collaborations

Throughout her career, Catherine has collaborated with notable professionals, including Johanna Chiche and Jean-Ehrland Ricci. These collaborations have further enriched her research and innovations.

Conclusion

Catherine Thieblemont's contributions to lymphoma research through her patents and collaborations highlight her role as an influential inventor in the medical field. Her innovative methods have the potential to significantly impact patient treatment and outcomes.